$10.74
0.46% yesterday
Nasdaq, Aug 11, 10:11 pm CET
ISIN
US45826J1051
Symbol
NTLA

Intellia Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief Medical Officer Edward J. Dulac - Executive Vice President, Chief Financial Officer and Treasurer John M.
Positive
The Motley Fool
5 days ago
Intellia (NTLA) Q2 Revenue Jumps 106%
Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Neutral
GlobeNewsWire
12 days ago
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia (NTLA) To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET.
Negative
Seeking Alpha
25 days ago
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Intellia Therapeutics. The stock lost 29% after news of a “safety concern” surfaced during a Phase III drug trial. The news looked terrible. A lab test showed indications that a patient was experiencin...
Positive
MarketBeat
28 days ago
In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a previous ceiling of 6,500, and flagged three stocks investors should have on their radar, including two index stalwarts and one off-the-beaten-path growth opportunity.
Neutral
24/7 Wall Street
about one month ago
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today